Literature DB >> 10602745

A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir.

S Chou1, C L Meichsner.   

Abstract

A deletion mutation (codons 595 to 603) in the cytomegalovirus (CMV) UL97 gene was recently reported after sequence analysis of leukocyte DNA from a patient receiving ganciclovir. The corresponding viral phenotype was examined by transfer of this mutation to a laboratory CMV strain (strain Towne). The recombinant virus was resistant to ganciclovir (8.4-fold increase in the 50% inhibitory concentration), was sensitive to foscarnet, and replicated normally in cell culture.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10602745      PMCID： PMC89650          DOI： 10.1128/AAC.44.1.183-185.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy.

Authors:  J C Mendez; I G Sia; K R Tau; M J Espy; T F Smith; S Chou; C V Paya
Journal:  Transplantation       Date:  1999-03-15       Impact factor: 4.939

Review 2.  Antiviral drug resistance in human cytomegalovirus.

Authors:  S Chou
Journal:  Transpl Infect Dis       Date:  1999-06       Impact factor: 2.228

3.  Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals.

Authors:  W L Drew; R Miner; E Saleh
Journal:  Clin Diagn Virol       Date:  1993-08

4.  Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids.

Authors:  G Kemble; G Duke; R Winter; R Spaete
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

5.  Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.

Authors:  S Chou; G Marousek; S Guentzel; S E Follansbee; M E Poscher; J P Lalezari; R C Miner; W L Drew
Journal:  J Infect Dis       Date:  1997-09       Impact factor: 5.226

6.  Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

Authors:  S Chou; A Erice; M C Jordan; G M Vercellotti; K R Michels; C L Talarico; S C Stanat; K K Biron
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

7.  The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase.

Authors:  D Michel; I Pavić; A Zimmermann; E Haupt; K Wunderlich; M Heuschmid; T Mertens
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.

Authors:  A Erice; C Gil-Roda; J L Pérez; H H Balfour; K J Sannerud; M N Hanson; G Boivin; S Chou
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

9.  The Cys607-->Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients.

Authors:  F Baldanti; M R Underwood; C L Talarico; L Simoncini; A Sarasini; K K Biron; G Gerna
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

10.  A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate.

Authors:  F Baldanti; E Silini; A Sarasini; C L Talarico; S C Stanat; K K Biron; M Furione; F Bono; G Palù; G Gerna
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103
View more
  12 in total

1.  Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency.

Authors:  D G Wolf; I Yaniv; S Ashkenazi; A Honigman
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient.

Authors:  Sébastien Hantz; Detlef Michel; Anne-Marie Fillet; Vincent Guigonis; Gaël Champier; Marie-Christine Mazeron; Albert Bensman; François Denis; Thomas Mertens; Axelle Dehee; Sophie Alain
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir.

Authors:  Gyu-Cheol Lee; Dong-Gun Lee; Su-Mi Choi; Jin-Hong Yoo; Sun-Hee Park; Jung-Hyun Choi; Woo-Sung Min; Ok-Hee Cho; Chan-Hee Lee; Wan-Shik Shin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.

Authors:  Sunwen Chou; Ronald J Ercolani; Adam L Vanarsdall
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

6.  Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.

Authors:  Gillian M Scott; Adriana Weinberg; William D Rawlinson; Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

7.  Successful ganciclovir treatment of primary cytomegalovirus infection containing the UL97 mutation N510S in an intestinal graft recipient.

Authors:  R Bachmann; K Hamprecht; J Lange; R Ladurner; S Nadalin; G Jahn; A Königsrainer; A Heininger
Journal:  Infection       Date:  2013-04-02       Impact factor: 3.553

Review 8.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

9.  Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay.

Authors:  Yoshiko Fukui; Keiko Shindoh; Yumiko Yamamoto; Shin Koyano; Isao Kosugi; Toyofumi Yamaguchi; Ichiro Kurane; Naoki Inoue
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

10.  Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus.

Authors:  Jocelyne Piret; Nathalie Goyette; Guy Boivin
Journal:  J Clin Microbiol       Date:  2016-06-01       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.